JY
ZNTL icon

Jeff Yass’s Zentalis Pharmaceuticals ZNTL Stock Holding History

Jeff Yass’s Portfolio ZNTL Stock Details ZNTL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$61.1K Sell
12,600
-32,700
-72% -$131K ﹤0.01% 12756
2026
Q1 		$106K Buy
+45,300
New +$117K ﹤0.01% 12308
2025
Q4 		– Sell
-10,400
Closed -$15.7K – 13814
2025
Q3 		$15.7K Buy
+10,400
New +$15.6K ﹤0.01% 12073
2025
Q2 		– Sell
-30,900
Closed -$49.1K – 13869
2025
Q1 		$49.1K Buy
30,900
+16,100
+109% +$34.7K ﹤0.01% 11872
2024
Q4 		$44.8K Sell
14,800
-18,200
-55% -$59.6K ﹤0.01% 11722
2024
Q3 		$121K Buy
+33,000
New +$120K ﹤0.01% 10912
2024
Q1 		– Sell
-30,200
Closed -$458K – 13530
2023
Q4 		$458K Buy
30,200
+12,800
+74% +$187K ﹤0.01% 8893
2023
Q3 		$349K Sell
17,400
-18,500
-52% -$470K ﹤0.01% 9030
2023
Q2 		$1.01M Buy
+35,900
New +$861K ﹤0.01% 6647
2021
Q3 		– Sell
-12,500
Closed -$665K – 13717
2021
Q2 		$665K Buy
+12,500
New +$669K ﹤0.01% 8871

Other funds holding ZNTL

5VM
5AM Venture Management San Francisco, California $288M AUM 313.93% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SCM
Squadron Capital Management Westmont, Illinois $322M AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $1.1B AUM 197.64% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

Jeff Yass's ZNTL Position: Q2 2026 in Review

Jeff Yass reduced its Zentalis Pharmaceuticals (ZNTL) stake by 62% in Q2 2026, selling an estimated $1.42M and leaving 215,113 shares worth $1.04M. The position accounts for ﹤0.01% of the portfolio, ranked #8096.

Jeff Yass first reported a position in ZNTL in Q4 2020 and has held it in 23 quarters since. The position peaked at $3.22M in Q3 2021. 113 funds tracked by Wall St. Rank hold ZNTL as of Q2 2026.

  • Jeff Yass held 215,113 shares of Zentalis Pharmaceuticals worth $1.04M as of Q2 2026.
  • Jeff Yass sold 356,144 Zentalis Pharmaceuticals shares in Q2 2026, an estimated $1.42M.
  • Zentalis Pharmaceuticals made up ﹤0.01% of Jeff Yass's portfolio in Q2 2026, its #8096 holding.
  • Jeff Yass first reported a position in Zentalis Pharmaceuticals in Q4 2020 and has held it in 23 quarters since.
  • Jeff Yass's Zentalis Pharmaceuticals position peaked at $3.22M in Q3 2021.
  • 113 funds tracked by Wall St. Rank held Zentalis Pharmaceuticals as of Q2 2026.

Based on Susquehanna International Group's 13F filing for Q2 2026, filed 14 Aug 2026.